Navigation Links
InterMune Announces Presentations of New Research in IPF at ERS
Date:8/27/2012

BRISBANE, Calif., Aug. 27, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that an oral presentation and three poster presentations related to the company's research programs in idiopathic pulmonary fibrosis (IPF) will be presented at the Annual Congress of the European Respiratory Society (ERS) being held in Vienna, Austria, September 1-5.

(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

New analyses of FVC change and Survival from the RECAP extension study of Esbriet® (pirfenidone) will be delivered in an oral presentation.  Additionally, new data on the long-term clinical safety of Esbriet in IPF patients who have received treatment for up to 7.7 years will be presented as part of a scientific poster discussion. 

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "These data demonstrate that the safety profile of Esbriet in IPF patients treated for several years is generally consistent with the well characterized safety profile from previous clinical studies.  Importantly, Esbriet is the first and only agent to demonstrate long-term clinical safety in a prospective well-designed study in patients with IPF."

Two additional scientific posters, including an analysis of safety outcomes in IPF patients treated with Esbriet and commonly used concomitant medications and the results of analyses that confirm the threshold defining clinically significant changes in the 6-minute walk test in patients with IPF will also be presented.

The schedule of presentations regarding Esbriet and/or IPF at ERS is as follows (all times CET):

Sunday, September 2, 2012
2:50-14:40 h
Thematic Poster Presentation
Dr. Carlo Albera:  "Safety and Tolerability of Pirfenidone in Patients w
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune to Divest Actimmune® (Interferon Gamma-1b)
2. InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 With advancements in neurological and ... is seeing new growth, according to Kalorama Information. ... for the majority of market volume, newer 3T ... which are creating opportunities for more sophisticated applications. The ... at a rate of 4%, with world market ...
(Date:12/17/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" ... offering of $125 million aggregate principal amount of 3.75% ... were offered and sold only to qualified institutional buyers ... 1933, as amended (the "Securities Act"). The ... per year, payable semiannually in arrears on June 15 ...
(Date:12/15/2014)... 15, 2014 Registreer nu via  ... und 20. Februar sind alle akkreditierten pharmazeutischen ... ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der ... die neue profitablen Unternehmensdienstleistungen, die für Apotheken ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Conference call webcast Monday, 5:00 p.m. EDT and ... and http://www.isispharm.com , MELBOURNE, Australia ... (ASX: ANP) and Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... the ATL/TV1102 Phase IIa clinical trial in patients ...
... BENEFIT is first and only prospectively planned 5-year study to ... lasting ... Bayer HealthCare Pharmaceuticals,announced today that new data from its BENEFIT ... that early,initiation of Betaseron(R) (interferon beta-1b) treatment in patients with,a ...
Cached Medicine Technology:ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 2ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 3ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 4ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 5ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 6ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis 7Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 2Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 3Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 4Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS 5
(Date:12/20/2014)... 2014 Recently, VogueQueen.com, a leading wedding ... Big Sale Online for 2015. Great discounts are ... and old consumers can get a discount, up to ... company’s website before January 30, 2015. , VogueQueen.com has ... launched a prom dress promotion. Many customers worldwide like ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and retailer, ... The company has recently updated its official blog with ... season, Angeldress Blog has recommended some new ... prides itself in offering a huge selection of elegant ... company’s outfits are very carefully selected based on the ...
(Date:12/20/2014)... CA (PRWEB) December 20, 2014 Atore, ... Innovation company just launched first birthday focused portal on ... “MERRY BIRTHDAY MESSAGE” launched in both US and Japan. ... BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY BIRTHDAY ... everyone’s birthday around the world. , Features, Choose from ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Recently, AngelWeddingDress.com ... Christmas Discount ”) for the coming Christmas. In the ... to 80% off. , “We have something special for ... for the holiday season. Moreover, our new collections of ... models are offered now at greatly discounted prices. Visit ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men ... and other serious side effects will be consolidated in ... coordinated pretrial proceedings, Wright & Schulte LLC reports. The ... order Friday to transfer 21 Xarelto lawsuits and over ... to the Louisiana district court for coordination by Judge ...
Breaking Medicine News(10 mins):Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4
... has been selected for the Physician of the Year Award by ... surgeon director in Otolaryngology at the same Infirmary, will be presented ... Nov 20 in New York., ,Mehta graduated in medicine from ... He has been affiliated with the Infirmary for more than 25 ...
... 50 percent of the clan is found battling chronic skin ... new study has claimed that nearly 50,000 hair stylists are ... shampoos that render constantly moist hands., ,Due to this, ... on with their jobs when the condition worsens. Hairdressers are ...
... more salt than the deep blue sea, according to a ... brings about a dramatic reduction in their blood pressure which ... disease and stroke later in life. ,The report states ... Twirls contain more than twice as much salt as the ...
... that although very difficult to disseminate actual figures it ... of the funds allocated for the disbursement of medicines ... or lost because of fraudulent practices, bribery and diversion ... assessed that governments spent about US$50 billion (€39 billion) ...
... killer H5N1 avian flu virus that had emerged in early ... resistant to the vaccination programme and might even be aided ... wave of transmission of H5N1 avian flu and could potentially ... of the Proceedings of National Academy of Sciences. ,The ...
... regularly, because the size of your paunch is directly related ... new research conducted by a medical expert of Indian origin. ... University of Leicester, obesity has now become a worldwide epidemic. ... currently over half of women and two-thirds of men in ...
Cached Medicine News:Health News:Hair-raising issues of hairdressers 2Health News:Kids' Food: Saltier than the Deep Blue Sea 2Health News:Kids' Food: Saltier than the Deep Blue Sea 3Health News:Kids' Food: Saltier than the Deep Blue Sea 4
... For practices that ... solution, the Burdick Vision,Premier ... powerful,diagnostic tool. The Vision ... choices and a,more comprehensive ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
The compact, simple-to-use ECG for medical professionals....
Medicine Products: